Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Where Tanox will take its HIV program

After languishing for almost two years,Tanox Biosystems Inc.'s anti-HIV monoclonal antibodies have been returned to the company by partner Ciba-Geigy Ltd.

Ciba completed a Phase I/II Swiss trial in 12 late-stage AIDS patients in October 1991 and reported on the safety

Read the full 410 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers